Advancing Innovative Technology into Safe and Effective Medicines

Video

Larry Altstiel, MD, PhD, EVP, Chief Medical Officer, vTv Therapeutics also discussed their team’s programs in type 2 diabetes surrounding an activator of an enzyme called glucokinase and a glucagon-like receptor agonist. “GLP-1s right now are all injectables, and they all have side effects of nausea and vomiting. In our particular case, ours is an oral molecule, and it also doesn’t seem to have the gastrointestinal side effects.”


Related Videos
Sorana Segal-Maurer, MD, an expert on HIV
Sorana Segal-Maurer, MD, an expert on HIV
Sorana Segal-Maurer, MD, an expert on HIV
Sorana Segal-Maurer, MD, an expert on HIV
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Shauna Applin, ARNP, an expert on HIV
Shauna Applin, ARNP, an expert on HIV
Shauna Applin, ARNP, an expert on HIV
Ralph DeFronzo, MD | Credit: UT San Antonio
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
© 2024 MJH Life Sciences

All rights reserved.